Greenwich LifeSciences Provides Update on Increased Patient Screen Rate in FLAMINGO-01
Rhea-AI Summary
Greenwich LifeSciences (Nasdaq: GLSI) reported an increased patient screen rate in its Phase III trial FLAMINGO-01 for GLSI-100. The annualized screening rate rose to over 800 patients per year, a ~33% increase from the prior 600 per year.
The company recorded ~200 patients screened per quarter across US and EU sites, attributing the rise to new sites activated in 2025 and stronger momentum at existing sites.
Positive
- Annual screen rate +33% to over 800 patients per year
- Quarterly peak of ~200 patients screened in the past 6 months
- New sites activated in 2025 contributing to higher enrollment
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
GLSI was down 1.19% while several biotech peers were up, including CHRS +3.77%, CLYM +3.36%, and MCRB +2.52%, suggesting a stock-specific move rather than a sector-wide trend.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 24 | Conference abstracts | Positive | +9.6% | AACR 2026 acceptance of two abstracts and posters for GLSI-100. |
| Jan 27 | Cash & financing update | Positive | +9.6% | Disclosure that 2025 ATM sales exceeded cash burn and boosted cash levels. |
| Jan 22 | FDA trial supply OK | Positive | +5.7% | FDA approval of commercially manufactured GP2 use in FLAMINGO-01 trial. |
| Dec 29 | Insider lock-up extension | Positive | +19.8% | Board extended director/officer lock-up to support FLAMINGO-01 and alignment. |
| Dec 22 | Trial & strategy update | Positive | +2.7% | Expanded FLAMINGO-01 site network, protocol plans, and ATM-funded strategy. |
Recent GLSI news has often been followed by positive single-day moves, with prior updates on FLAMINGO-01, FDA progress, and governance changes showing gains of 9.6%, 9.62%, 5.65%, and 19.8%.
Over the past months, GLSI has focused on advancing the Phase III FLAMINGO-01 trial of GLSI-100 and shoring up its financial and governance position. Updates included AACR 2026 abstract acceptances on Feb 24, 2026, cash burn and ATM financing details on Jan 27, 2026, and FDA approval for commercially manufactured GP2 in FLAMINGO-01 on Jan 22, 2026. A board-extended insider lock-up and broader trial and corporate strategy update were disclosed in late Dec 2025.
Market Pulse Summary
This announcement underscores operational momentum in FLAMINGO-01, with screening rising to over 800 patients per year versus 600 previously. Combined with earlier updates on trial progress, financing via an ATM, and FDA clearance of commercial GP2 supply, GLSI has emphasized advancing GLSI-100 while managing resources. Investors may watch enrollment sustainability, future financing disclosures, and upcoming scientific presentations as key markers of execution and risk management.
Key Terms
phase iii medical
fast track regulatory
immunotherapy medical
AI-generated analysis. Not financial advice.
STAFFORD, Texas, March 03, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided an update on the increased patient screen rate in FLAMINGO-01.
FLAMINGO-01 Annual Patient Screen Rate Increases to Over 800 Patients per Year
Over the past 6 months, the Company achieved its highest screening rate of approximately 200 patients per quarter or the equivalent of over 800 patients per year in the US and EU sites, which is an approximately
CEO Snehal Patel commented, "While the approximately
About FLAMINGO-01 Open Label Phase III Data
More than 1,000 patients have been screened with a current screen rate of approximately 800 patients per year. The 250 patient non-HLA-A*02 arm is now fully enrolled, where all patients received GLSI-100, which is 5 times more treated patients and recurrence rate data than the approximately 50 patients treated in the Phase IIb trial. The Primary Immunization Series (PIS), which includes the first 6 GLSI-100 injections over the first 6 months and is required to reach peak protection, is followed by 5 booster injections given every 6 months to prolong the immune response, thereby providing longer-term protection.
- In the non-HLA-A*02 arm, a preliminary analysis of recurrence rates after the PIS is completed shows an approximately
80% reduction in recurrence rate. - This observation is trending similarly to the Phase IIb trial results and hazard ratio where HLA-A*02 patients were treated and where breast cancer recurrences were reduced up to
80% compared to a 20-50% reduction in recurrence rate by other approved products. - The immune response at baseline prior to any GLSI-100 treatment, the increasing immune response during the PIS, and the safety profile of non-HLA-A*02 patients is trending similarly to the HLA-A*02 arms of FLAMINGO-01 and to the Phase IIb study.
Analysis of the open label data from FLAMINGO-01 has been conducted in a manner that maintains the study blind. The open label recurrence rate, immune response, and safety data is based on the patients enrolled to date in FLAMINGO-01 and the data provided by the clinical sites so far, which is not completed or fully reviewed, and is thus preliminary. While comparing any preliminary FLAMINGO-01 data to the Phase IIb clinical trial data may be possible, these preliminary results are not a prediction of future results, and the results at the end of the study may differ.
About GLSI-100 Phase IIb Study
In the prospective, randomized, single-blinded, placebo-controlled, multi-center (16 sites led by MD Anderson Cancer Center) Phase IIb clinical trial of HLA-A*02 breast cancer patients, 46 HER2/neu 3+ over-expressor patients were treated with GLSI-100, and 50 placebo patients were treated with GM-CSF alone. After 5 years of follow-up, there was an
80% or greater reduction in metastatic breast cancer recurrence rate over 5 years of follow-up with a peak immune response at 6 months and well-tolerated safety profile.- The PIS elicited a potent immune response as measured by local skin tests and immunological assays.
About FLAMINGO-01 and GLSI-100
FLAMINGO-01 (NCT05232916) is a Phase III clinical trial designed to evaluate the safety and efficacy of Fast Track designated GLSI-100 (GP2 + GM-CSF) in HER2 positive breast cancer patients who had residual disease or high-risk pathologic complete response at surgery and who have completed both neoadjuvant and postoperative adjuvant trastuzumab based treatment. The trial is led by Baylor College of Medicine and currently includes US and European clinical sites from university-based hospitals and academic and cooperative networks with plans to open up to 150 sites globally. In the double-blinded arms of the Phase III trial, approximately 500 HLA-A*02 patients are planned to be randomized to GLSI-100 or placebo, and up to 250 patients of other HLA types are planned to be treated with GLSI-100 in a third arm. The trial has been designed to detect a hazard ratio of 0.3 in invasive breast cancer-free survival, where 28 events will be required. An interim analysis for superiority and futility will be conducted when at least half of those events, 14, have occurred. This sample size provides
For more information on FLAMINGO-01, please visit the Company's website here and clinicaltrials.gov here. Contact information and an interactive map of the majority of participating clinical sites can be viewed under the "Contacts and Locations" section. Please note that the interactive map is not viewable on mobile screens. Related questions and participation interest can be emailed to: flamingo-01@greenwichlifesciences.com
About Breast Cancer and HER2/neu Positivity
One in eight U.S. women will develop invasive breast cancer over her lifetime, with approximately 300,000 new breast cancer patients and 4 million breast cancer survivors. HER2 (human epidermal growth factor receptor 2) protein is a cell surface receptor protein that is expressed in a variety of common cancers, including in
About Greenwich LifeSciences, Inc.
Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2 protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in
Forward-Looking Statement Disclaimer
Statements in this press release contain "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will," "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Greenwich LifeSciences Inc.'s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including statements regarding the intended use of net proceeds from the public offering; consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section entitled "Risk Factors" in Greenwich LifeSciences' Annual Report on the most recent Form 10-K for the year ended December 31, 2024, and other periodic reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Greenwich LifeSciences, Inc. undertakes no duty to update such information except as required under applicable law.
Company Contact
Snehal Patel
Investor Relations
Office: (832) 819-3232
Email: info@greenwichlifesciences.com
Investor & Public Relations Contact for Greenwich LifeSciences
Dave Gentry
RedChip Companies Inc.
Office: 1-800-RED CHIP (733 2447)
Email: dave@redchip.com
FAQ
What is Greenwich LifeSciences (GLSI) reporting about FLAMINGO-01 patient screening in March 2026?
How much did FLAMINGO-01 screening increase compared to prior reported rates for GLSI?
What screening velocity did Greenwich achieve recently for GLSI's Phase III FLAMINGO-01 trial?
Do the FLAMINGO-01 screening updates for GLSI indicate enrollment is accelerating?
Will Greenwich (GLSI) likely reach a higher peak screening rate for FLAMINGO-01 soon?
